StockData
Climb Bio, Inc. logo

Climb Bio, Inc. (CLYM) KPIs and segments

CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$9.94−0.42 (-4.05%)

Close on Nov 16, 2026Market cap $570.92MP/E –Yield –

KPIs & segments

Operating metrics and segments that drive Climb Bio's business

Climb Bio's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Add to chartMetric
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
United Kingdom($M)
-0.27-6.76-17.4-39.0-34.2-15.6
United States($M)
-59.6-67.1-17.8-6.27-13.3-5.08

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).

Data updated 2026-03-05.

See a number that looks wrong?